ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 993

Anti-Citrullinated Proteins Antibodies Promote Synovial Fibroblast Migration in Rheumatoid Arthritis

Meng Sun1, Vijay Joshua1, Aase Haj Hensvold1, Sergiu-Bogdan Catrina2, Lars Klareskog3, Vivianne Malmström4, Heidi Wähämaa1 and Anca I Catrina1, 1Medicine, Rheumatology Unit, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, 2Molecular Medicine and Surgery, Molecular Medicine and Surgery, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden, 3Department of Medicine, Rheumatology Unit, Karolinska Institute, Stockholm, Sweden, 4Medicine, Rheumatology Unit, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: ACPA, fibroblasts and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Title: B cell Biology and Targets in Autoimmune Disease: Rheumatoid Arthritis and Related Diseases

Session Type: Abstract Submissions (ACR)

Background/Purpose

The presence of anti-citrullinated proteins antibodies (ACPAs) in RA is associated with aggressive disease phenotype and bone destruction. As synovial fibroblasts (SFs) are considered key players of both synovial inflammation and bone destruction in rheumatoid arthritis (RA), we studied the effect of ACPAs on fibroblasts migration.

Methods

Human dermal fibroblasts (HDFs) were obtained from PromoCell. SFs were isolated from synovial tissue of RA patients (RASFs) by enzymatic digestion. ACPA positive and negative IgGs were separated from plasma of RA patients and monoclonal anti-citrullinated antibodies were generated from RA synovial fluid by single B-cells1. Migration scratch assays were performed using either RASFs or HDFs to test the effect of ACPAs, anti-citrullinated monoclonal antibodies and appropriate negative controls. The effect of a phosphatidyl inositol-3-kinase (PI3K) inhibitor (wortmannin) and a focal adhesion kinase (FAK) inhibitor (PF-573228) was tested. Light microscopy images were taken at baseline and after 6 hours incubation and analyzed using NIH ImageJ to calculate migration index. Cytotoxicity and proliferation assays were done in parallel with migration assays. 

Results

ACPAs but not control IgGs induced a 3.9±0.5 (mean±SD) fold increase in HDFs and a 2.6±0.5 (mean±SD) fold increase in RASFs migration (p<0.05). PI3K but not FAK inhibition almost completely abolished ACPAs effects, with minimal fold migration increase of 1.4±0.4 (mean±SD). No difference in either cytotoxicity or proliferation rate were observed between different treatments. One out of three different anti-citrullinated monoclonal antibodies displayed similar mig

Conclusion

We describe a novel effect of ACPAs, providing a link between synovial fibroblasts and the adaptive immune system. We further suggest that different fine specificities of ACPAs might have distinct impact on disease pathogenesis.

1.         Amara, K. et al. Monoclonal IgG antibodies generated from joint-derived B cells of RA patients have a strong bias toward citrullinated autoantigen recognition. J Exp Med 210, 445-55 (2013).


Disclosure:

M. Sun,
None;

V. Joshua,
None;

A. H. Hensvold,
None;

S. B. Catrina,
None;

L. Klareskog,
None;

V. Malmström,
None;

H. Wähämaa,
None;

A. I. Catrina,
None.

  • Tweet
  • Email
  • Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/anti-citrullinated-proteins-antibodies-promote-synovial-fibroblast-migration-in-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology